Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.

Men more sensitive to blue light

11 Nov 2017
The cornea, the transparent outermost layer of the eye, protects the eye from infection and physical injury.

Sensitivity to blue-enriched light is influenced by sex differences, such that males display a stronger response even to very low light levels, a recent study suggests. Moreover, sex differences also affect the acute benefits of bedtime blue light exposure such as sustained attention.

In the study, 32 participants (mean age 25.2±3.1 years; 50 percent female) were subjected to 1.5 hours of dim light (<8 lx), 2 hours of darkness, 2 hours of light exposure (40 lx) and 45 minutes of dim light (<8 lx), in sequence, until habitual sleep time. Both groups were matched according to age, ethnicity and body mass index.

Males preferred the 40-lx light delivered by a 6,500-K than by a 2,500-K fluorescent lamp (62.5 vs 37.5 percent). An opposite trend was observed for females (12.5 vs 87.5 percent, respectively), with the difference between the sexes reaching significance (p=0.004).

In a posthoc analysis, males were found to perceive the 6,500-K light as significantly stronger than the 2,500-K light (mean, 85.6±4.5 vs 67.7±5.4).

Light condition, specifically the 6,500-K light, significantly improved the median response time (p<0.005) and 10-percent fastest response time (p<0.001) exclusively in males. No such effect was observed in females.

Moreover, following exposure to 6,500-K light before bedtime, males had significantly higher frontal nonrapid eye movement slow-wave activity (2 to 4 Hz) sleep electroencephalogram power density than women (p<0.05).

“Collectively, the data indicate that sex differences in light sensitivity might play a key role for ensuring the success of individually-targeted light interventions,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.